Evidence on the safety of extracorporeal shockwave therapy for calcific tendinopathy in the shoulder shows no major safety concerns in the short term. Evidence on efficacy is inadequate. Therefore, ...
SANTA CLARA, Calif. and SINGAPORE, May 23, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified ...
FREMONT, Calif. & WASHINGTON--(BUSINESS WIRE)--Shockwave Medical, a pioneer in the treatment of calcified cardiovascular disease, today reported positive safety, performance and intravascular imaging ...
FREMONT, Calif. & LAS VEGAS--(BUSINESS WIRE)--Shockwave Medical, a pioneer in the treatment of calcified cardiovascular disease, today announced positive clinical results from the pooled DISRUPT PAD ...
SANTA CLARA, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of ...
FREMONT, Calif., Shockwave Medical, a pioneer in the treatment of calcified cardiovascular disease, today announced clearance from the U.S. Food and Drug Administration (FDA) of the Lithoplasty ® ...
Evidence on the safety of extracorporeal shockwave therapy for calcific tendinopathy in the shoulder shows no major safety concerns in the short term. Evidence on efficacy is inadequate. Therefore, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results